CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.
  
  LEARNING OBJECTIVES

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability/mismatch repair deficiency status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into treatment algorithms.
  • Incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer after disease progression on front-line therapy.
  • Appraise clinical trial findings supporting the use of neoadjuvant and/or adjuvant anti-PD-1/PD-L1 antibody therapy for patients with resectable gastric, GEJ and esophageal cancers, and discern the clinical applicability of various treatment strategies.
  • Recall available data with novel HER2-targeted agents and strategies for patients with newly diagnosed or previously treated HER2-overexpressing gastric/GEJ cancer, and identify candidates for these approaches.
  • Evaluate the biological rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess available data with novel strategies directed at this emerging biomarker.
  • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  David H Ilson, MD, PhD
  Attending Physician, Member
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Consulting Agreements: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Merck, Roche Laboratories Inc, Taiho Oncology Inc.
  
  Rutika Mehta, MD, MPH
  Associate Member in the Department of Gastrointestinal Oncology
  Moffitt Cancer Center
  Associate Professor in the Department of Oncologic Sciences
  University of South Florida
  Tampa, Florida
  
  Advisory Committee: Astellas, BostonGene, Bristol Myers Squibb, Eisai Inc, Guardant Health, Lilly, Merck, Natera Inc, Novartis, Seagen Inc; Consulting Agreement: Lilly; Data and Safety Monitoring Board/Committee: Arcus Biosciences.
  
  Markus Moehler, MD
  Head, Gastrointestinal Oncology
  Research Center for Immunotherapy (FZI)
  Past Chair of EORTC Gastrointestinal Cancer Group
  Johannes Gutenberg-University Clinic
  Mainz, Germany
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, MSD, Servier Pharmaceuticals LLC; Contracted Research (With My University Clinic): Leap Therapeutics Inc, MSD, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Transcenta; Speakers Bureau: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, MSD, Sanofi, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Triptych.
  
  Manish A Shah, MD
  Chief, Solid Tumor Oncology Service
  Director, Gastrointestinal Oncology Program
  Co-Director, Center for Advanced Digestive Care
  Bartlett Family Professor of Gastrointestinal Oncology
  Weill Cornell Medicine/NewYork-Presbyterian Hospital
  New York, New York
  
  Contracted Research: Bristol Myers Squibb, Merck, Oncolys BioPharma.
  
  MODERATOR — Harry H Yoon, MD, MHS Advisory Committee: ALX Oncology, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Elevation Oncology, MacroGenics Inc, Merck, Novartis, OncXerna Therapeutics Inc, Zymeworks Inc; Consulting Agreements: Amgen Inc, Merck; Contracted Research: Amgen Inc, BeiGene Ltd, Bristol Myers Squibb, CARsgen Therapeutics, MacroGenics Inc, Merck.
  
  SURVEY PARTICIPANTS
  Jaffer A Ajani, MD — Advisory Committees and Consulting Agreements: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Merck, Sanofi, Taiho Oncology Inc; Contracted Research: BeiGene Ltd, Bristol Myers Squibb, Delta-Fly Pharma Inc, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Merck, Roche Laboratories Inc, Transcenta; Data and Safety Monitoring Board/Committee: BeiGene Ltd. Sunnie Kim, MD — Advisory Committees: Astellas, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, I-Mab Biopharma, Merck; Contracted Research: Merck.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, BeiGene Ltd, Bristol Myers Squibb, and Lilly.
  
  Release date: February 2024
  Expiration date: February 2025